European Journal of Obstetrics & Gynecology and Reproductive Biology
Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy
Introduction
Biochemical screening for Down syndrome by means of the triple-marker test (alpha- chorionic gonadotropin+unconjugated estriol) has been successfully used in antenatal care for more than 10 years. Although different biochemical [1], [2], [3] and ultrasound [4] markers changed non-invasive approach to Down syndrome diagnosis, triple-marker test is still in clinical practice due to improvements even today [5]. Because of the origin and sites of metabolism, chorionic gonadotropin, alpha-fetoprotein and estriol are markers of the feto-placental unit during pregnancy. Its function can be changed even if fetus has normal karyotype. Since the introduction of triple-marker test in screening for Down syndrome [6], a lot of work has been done to evaluate implications of atypical alpha-fetoprotein, chorionic gonadotropin and unconjugated estriol levels on adverse pregnancy outcome [7], [8], [9], [10], [11], [12], [13]. Still, there appear to be conflicting data as to the association of biochemical markers and pregnancy complications, and some papers have seriously questioned the usefulness of such tests [8], [13]. Study design specificities and variations of marker levels in different populations could be the explanation for such controversies. That is why we analyzed the relationship between pregnancy outcome and abnormal maternal second trimester biochemistry in a relatively homogeneous population of Croatia and after having set our own population standards for all three markers [14].
Section snippets
Materials and methods
During the 1996–1998 period, 2384 pregnant women were enrolled in the antenatal care program—1707 of them due to age (35 years or older) and 677 women younger than 35 on their own request, or when indicated by a history of fetal aneuploidy. Blood samples were obtained between 15 and 22 weeks of gestation and fetal biparietal diameter was ultrasonographically measured for gestational dating. Previous Down syndrome was reported in 63 (2.6%) women. Prenatal karyotyping was performed in all women
Results
Relative risks for the occurrence of various pregnancy complications in euploid gestations according to biochemical marker results are shown in Table 1. There were 40 euploid pregnancies with high alpha-fetoprotein levels, considered borderline positive for NTD. Among them, gestations with IUGR (odds ratio=2.7), spontaneous abortion (odds ratio=4.4), and intrauterine fetal death (odds ratio=5.8) were significantly more frequent (P<0.05). Total human chorionic gonadotropin (ThCG) levels equal or
Discussion
Biochemical markers of Down syndrome in maternal circulation are of fetal/placental origin and not directly related to chromosome 21. By means of main step through screening for Down syndrome (transformation of individual marker level to MoM value) we screen in general for all disorders of their synthesis and metabolism in fetal and placental tissues. During this study, atypical concentrations of alpha-fetoprotein, chorionic gonadotropin and unconjugated estriol were observed in relation to
Acknowledgements
This study was in part supported by a research grant no.108-250 from the Scientific Research Funds of the Ministry of Science of Croatia.
References (22)
- et al.
Maternal serum Down’s syndrome screening: free-beta protein is a more effective marker than human chorionic gonadotropin
Am. J. Obstet. Gynaecol.
(1990) - et al.
Ultrasonographic detection of the second-trimester fetus with trisomy 18 and 21
Am. J. Obstet. Gynecol.
(1990) - et al.
Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein
Obstet. Gynecol.
(1996) - et al.
Second-trimester maternal marker screening: maternal serum alpha-fetoprotein, beta human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome
Am. J. Obstet. Gynecol.
(1999) - et al.
The triple-marker test in predicting fetal aneuploidy: a compromise between sensitivity and specificity
Eur. J. Obstet. Gynecol. Reprod. Biol.
(2000) - et al.
Maternal serum Down’s syndrome screening: unconjugated estriol is not useful
Am. J. Obstet. Gynecol.
(1990) - et al.
Second trimester maternal serum immuno-reactive inhibin as a marker for fetal Down’s syndrome
Prenat. Diagn.
(1992) - et al.
Urinary β-core human chorionic gonadotropin: a new approach to Down’s syndrome screening
Prenat. Diagn.
(1994) - et al.
Combined use of genetic sonography and maternal serum triple-marker screening: an effective method for increasing the detection of trisomy 21 in women younger than 35 years
J. Ultrasound Med.
(2000) - et al.
Maternal serum screening for Down’s syndrome in early pregnancy
Br. Med. J.
(1988)
Increased maternal serum alpha-fetoprotein and human chorionic gonadotropin in compromised pregnancies other than for neural tube defects or Down syndrome
Prenat. Diagn.
Cited by (45)
The association between human chorionic gonadotropin and adverse pregnancy outcomes: a systematic review and meta-analysis
2024, American Journal of Obstetrics and GynecologySerum markers in quadruple screening associated with adverse pregnancy outcomes: A case–control study in China
2020, Clinica Chimica ActaCitation Excerpt :In GDM, increased hCG synthesis is a compensatory response to placental pathology. A low concentration of uE3 is associated with oligohydramnios, GDM, preterm delivery, fetal loss, and SGA [10,19,20]. The results of our regression analysis suggest that a low uE3 concentration is a risk factor for hypertension during pregnancy.
Associations of serum markers screening for Down's syndrome with pregnancy outcomes: A Chinese retrospective cohort study
2019, Clinica Chimica ActaCitation Excerpt :Increased concentrations of AFP and HCG were correlated with functional disturbance of placenta resulting in abnormal obstetric outcomes [6]. Up till to now, these reported outcomes include hypertension, miscarriage, FGR, fetal death, placental abruption, PE, and PTB [19–24]. Our results showed that PTB group had statistically significantly higher concentration of AFP than the full term birth (FTB) group; maternal high AFP concentrations significantly increased the risk of PTB and SGA infants supporting previous studies.
Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers
2018, American Journal of Obstetrics and GynecologyScreening for fetal aneuploidy
2016, Seminars in PerinatologyCitation Excerpt :The risk of having an adverse outcome is significantly increased if a patient has two or more abnormal markers.42 Both singleton and twin pregnancies with elevated hCG and AFP have been associated with adverse obstetric outcomes.43–45 Women with low estriol (<0.75 MoM) have been found to have an increased risk of adverse outcome, including IUGR, oligohydramnios, and delivery of small-for-gestational-age infants, a risk that seems independent of elevated hCG or AFP.46
Regression of hepatocarcinoma cells using RNA aptamer specific to alpha-fetoprotein
2012, Biochemical and Biophysical Research CommunicationsCitation Excerpt :AFP is most commonly detected in HCC (almost 70% of tumors) and is implicated in the development of HCC. Moreover, abnormal serum levels of AFP are associated with neural tube defects, brain/spinal cord malformations, chromosomal abnormalities (aneuploidies), and various anatomic congenital disorders [5–8]. Therefore, AFP has been used both as a tumor monitoring agent and as an indicator for possible fetal neural tube defects and aneuploidies.